Printer Friendly

Osiris Therapeutics Inc appoints Dr. Lode Debrabandere as COO.

M2 EQUITYBITES-October 23, 2012-Osiris Therapeutics Inc appoints Dr. Lode Debrabandere as COO(C)2012 M2 COMMUNICATIONS http://www.m2.com

Stem cell drug company Osiris Therapeutics Inc (NasdaqGM:OSIR) revealed on Monday the promotion of Lode Debrabandere, PhD to chief operating officer (COO), reporting to its chief executive officer, Dr. C. Randal Mills.

Most recently, Dr. Debrabandere has served as senior vice president of Therapeutics of Osiris Therapeutics Inc, which he joined in 2006.

Prior to Osiris, Dr. Debrabandere served as vice president of Global Marketing with Bristol-Myers Squibb, including the role of global brand leader for Abilify.

Previously, Dr. Debrabandere led the marketing department of UCB Pharma Inc as well as served as the head of worldwide clinical operations at UCB Pharma Inc.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Oct 23, 2012
Words:135
Previous Article:TCS receives USD18m in funded orders from US Army for SNAP deployable satellite systems support.
Next Article:United Stationers to acquire O.K.I. Supply Co for USD90m cash.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters